Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population
Journal article
Ashdown HF. et al, (2022), ERJ Open Research, 8, 00606 - 2021
Discordant diagnostic criteria for pneumonia in COPD trials: a review
Journal article
Wise RA. et al, (2021), European Respiratory Review, 30, 210124 - 210124
Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant
Journal article
Turnbull CD. et al, (2021), BMJ Open Respiratory Research, 8, e001044 - e001044
Overcoming Therapeutic Inertia to Reduce the Risk of COPD Exacerbations: Four Action Points for Healthcare Professionals
Journal article
Singh D. et al, (2021), International Journal of Chronic Obstructive Pulmonary Disease, Volume 16, 3009 - 3016
Renaming COPD exacerbations: the UK respiratory nursing perspective.
Journal article
Mwasuku C. et al, (2021), BMC pulmonary medicine, 21
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial (vol 398, pg 843, 2021)
Journal article
Yu L-M. et al, (2021), LANCET, 398, E12 - E12
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Journal article
Yu L-M. et al, (2021), The Lancet, 398, 843 - 855
Predicting treatment outcomes following an exacerbation of airways disease
Journal article
Halner A. et al, (2021), PLOS ONE, 16, e0254425 - e0254425
A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial.
Journal article
Bafadhel M. et al, (2021), Eur Respir J
Eosinophilic inflammation, coronavirus disease 2019, and asthma: Are inhaled corticosteroids the missing link?
Journal article
Ramakrishnan S. and Bafadhel M., (2021), Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 127
Research priorities for exacerbations of COPD.
Journal article
Alqahtani JS. et al, (2021), The Lancet. Respiratory medicine, 9, 824 - 826
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
Journal article
Ramakrishnan S. et al, (2021), LANCET RESPIRATORY MEDICINE, 9, 763 - 772
Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
Journal article
Pavord I. et al, (2021), International Journal of Chronic Obstructive Pulmonary Disease, Volume 16, 1755 - 1770
Inhaled budesonide for early treatment of COVID-19 - Authors' reply.
Journal article
Ramakrishnan S. and Bafadhel M., (2021), The Lancet. Respiratory medicine
Antimicrobial Peptides SLPI and Beta Defensin-1 in Sputum are Negatively Correlated with FEV1
Journal article
Cane JL. et al, (2021), International Journal of Chronic Obstructive Pulmonary Disease, Volume 16, 1437 - 1447
A Comprehensive Analysis of the Stability of Blood Eosinophil Levels
Journal article
Chipps BE. et al, (2021), Annals of the American Thoracic Society
Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
Journal article
Yu L-M. et al, (2021)
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
Journal article
Ramakrishnan S. et al, (2021), The Lancet. Respiratory medicine
Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
Journal article
Bourbeau J. et al, (2021), International Journal of Chronic Obstructive Pulmonary Disease, Volume 16, 499 - 517
Infection, inflammation and intervention: mechanistic modelling of epithelial cells in COVID-19.
Journal article
Fadai NT. et al, (2021), J R Soc Interface, 18